Ovid Therapeutics (OVID) Net Cash Flow Growth (3y) (2019 - 2026)
Ovid Therapeutics (OVID) Net Cash Flow Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 32.17% |
| 10 | Ovid Therapeutics | 120.41 Mn | -35.11 Mn | - | 64.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64.56% |
| Dec 31, 2025 | 18.47% |
| Sep 30, 2025 | 18.92% |
| Jun 30, 2025 | 27.59% |
| Mar 31, 2025 | 37.47% |
| Dec 31, 2024 | 43.20% |
| Sep 30, 2024 | -12.21% |
| Jun 30, 2024 | 62.78% |
| Mar 31, 2024 | -71.49% |
| Dec 31, 2023 | -27.02% |
| Sep 30, 2023 | -32.21% |
| Jun 30, 2023 | -14.92% |
| Mar 31, 2023 | 48.11% |
| Dec 31, 2022 | -74.97% |
| Sep 30, 2022 | -15.47% |
| Jun 30, 2022 | -134.93% |
| Mar 31, 2022 | -46.85% |
| Dec 31, 2021 | -58.96% |
| Sep 30, 2021 | -48.91% |
| Jun 30, 2021 | -46.32% |